Yes, Rinvoq (upadacitinib) is classified as a specialty drug. Major insurers like Aetna list it under their specialty pharmacy clinical policy bulletins, and prescriptions are typically filled through specialty pharmacies rather than your local retail pharmacy. This classification affects how you get the medication, what it costs, and how much paperwork is involved before your first dose.
Why Rinvoq Is Classified as Specialty
Specialty drugs are medications that treat complex, chronic conditions and come with higher costs, stricter insurance requirements, or the need for ongoing clinical monitoring. Rinvoq checks several of those boxes. It belongs to a class of drugs called JAK inhibitors, which work by dialing down an overactive immune system. That mechanism is powerful but comes with serious safety considerations: the FDA requires a boxed warning on Rinvoq covering increased risks of heart-related events, cancer, blood clots, and death. These risks are significant enough that the FDA has limited all approved uses of Rinvoq to patients who haven’t responded to, or can’t tolerate, an older category of treatment called TNF blockers.
Rinvoq also requires blood work before you start and at regular intervals while you’re on it. Your doctor will check your white blood cell counts, hemoglobin, liver enzymes, and cholesterol levels. You’ll also need screening for tuberculosis and hepatitis B and C before beginning treatment. That level of ongoing lab monitoring is one of the hallmarks of a specialty medication.
Where You Can Fill the Prescription
Unlike some specialty drugs that are restricted to a handful of pharmacies, Rinvoq uses what’s called open distribution. That means your prescription can go to any specialty pharmacy you choose, and all specialty pharmacies can dispense and ship it. You won’t be locked into a single provider. Specialty pharmacies differ from regular retail pharmacies in that they’re set up to handle medications with complex access requirements and typically offer dedicated patient support, including help navigating insurance approvals.
From a storage standpoint, Rinvoq is relatively simple. It’s an oral tablet stored at room temperature (up to 77°F) in its original bottle to protect from moisture. It doesn’t require refrigeration or special handling at home, which makes it less burdensome than injectable specialty drugs that need cold chain shipping.
Prior Authorization and Step Therapy
Because Rinvoq is a specialty drug, your insurance will almost certainly require prior authorization before covering it. This means your doctor has to submit documentation proving you meet specific criteria. The exact requirements vary by insurer and by condition, but a Medicaid example for atopic dermatitis gives a good sense of how detailed they get:
- Diagnosis threshold: You typically need moderate to severe disease, such as at least 10% of body surface area affected for eczema.
- Failed prior treatments: You’ll need documented trials of other therapies first, often including topical steroids, topical calcineurin inhibitors, and at least one systemic medication.
- Specialist involvement: The prescription usually must come from, or be made in consultation with, a relevant specialist.
- Reauthorization: Initial approval may last only six months, after which your doctor submits again to show the drug is working. Subsequent approvals may extend to one year.
This step therapy requirement, where you must try and fail cheaper treatments first, is standard for specialty drugs in this class. Plan for the approval process to take days to weeks, and ask your doctor’s office to start the paperwork early.
What Rinvoq Treats
Rinvoq is FDA-approved for several autoimmune and inflammatory conditions, which is part of why it sits in the specialty category. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (a type of inflammatory spinal arthritis), Crohn’s disease, ulcerative colitis, and moderate to severe atopic dermatitis (eczema). In every case, it’s positioned as a later-line option for people whose disease hasn’t been adequately controlled by other treatments.
Cost and Financial Assistance
Specialty drug pricing is one of the main reasons people search for this classification, and Rinvoq is expensive. The manufacturer, AbbVie, offers a copay assistance program through RINVOQ Complete that covers up to $14,000 per calendar year for eligible patients with commercial insurance. A separate rebate benefit covers up to $1,000 per year toward lab tests required for monitoring.
There are important limitations. The copay card is not available if you’re on any government-funded insurance, including Medicare Part D, Medicaid, TRICARE, or VA programs. If your commercial plan uses a copay maximizer or accumulator program (where manufacturer assistance doesn’t count toward your deductible or out-of-pocket max), AbbVie may cap support at $4,000. It’s worth calling RINVOQ Complete directly to understand what your actual out-of-pocket cost will look like before starting treatment.
What Ongoing Monitoring Looks Like
Once you’re on Rinvoq, expect routine blood draws. Your doctor will monitor your white blood cell counts (both neutrophils and lymphocytes), hemoglobin, and liver enzymes on a schedule they determine based on your health. Cholesterol levels get checked around 12 weeks after starting and periodically after that, since JAK inhibitors can raise lipid levels. If any of these values fall outside safe ranges, your doctor may pause or stop the medication.
This monitoring isn’t optional or a one-time thing. It continues for as long as you take the drug. Specialty pharmacies are equipped to help coordinate these requirements, and some will send reminders when lab work is due.